As the Congressional Budget Office (CBO) projects a $1.9 trillion federal deficit for fiscal year 2026, Congress is under increasing pressure to identify durable budget pay-fors. In most cases, that discussion quickly narrows to three familiar choices: raise domestic taxes, cut spending, or continue borrowing more. But tariffs warrant more serious consideration.
The CPA Domestic Market Share Index (DMSI) has rebounded sharply in 2025, signaling that U.S. tariffs are beginning to restore domestic production’s share of the American market.
One year after Liberation Day, the U.S. manufacturing sector is showing some significant early signs of resurgence. The industrial base is not yet fully rebuilt, and the recovery remains uneven across sectors, but the early signs are encouraging.
Cheap imports shaved prices on some goods but never made Americans richer. Wage losses and job destruction outweighed any discounts.
The United States is facing a new form of strategic dependence: Chinese-linked firms are reentering critical American industries through influence and control rather than visible ownership.
KEY POINTS Beef prices are at record highs—not because of U.S. ranchers or tariffs, but because dependence on foreign imports and meatpacker consolidation have distorted
The August 2025 inflation report has reignited debate over tariffs. Some pundits have been quick to blame trade policy for rising prices, invoking Smoot-Hawley comparisons and warning of disaster on the scale of the Great Depression. But the data tells a different story.
America is dangerously reliant on high-risk foreign suppliers for essential generic drugs, especially APIs concentrated in China and India. That over-reliance has already triggered preventable crises, such as nationwide chemotherapy shortages when a single overseas plant shut down.
The African Growth and Opportunity Act (AGOA), enacted in 2000, was designed to promote economic development and democratic reform in Sub-Saharan Africa by granting duty-free access to the U.S. market for thousands of products.
America’s generic drug supply is at a crisis point. As detailed in previous reports, the United States is dangerously reliant on a high-risk imported drug supply, and today’s widespread drug shortages stem not from shipping delays or unexpected demand—but from a collapse in domestic production.
